Literature DB >> 10792785

Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.

K Morita1, Y Ono, H Fukui, S Tomita, Y Ueda, A Terano, T Fujimori.   

Abstract

Clarification of the pathogenic relationships existing among ovarian cystadenomas, tumors of low malignant potential (LMP) and various adenocarcinoma types, a series of 29 mucinous and 19 serous ovarian tumors including adenomas, LMP tumors and adenocarcinomas were examined. P53 protein was detected by the streptavidin-biotin method and point mutation of K-ras codon 12 was detected by polymerase chain reaction-restriction fragment length polymorphism analysis. P53 overexpression was observed more frequently in serous adenocarcinomas (5/8, 63%) than in mucinous adenocarcinomas (2/9, 22%) and was correlated with the malignant potential of serous tumors. Furthermore, the proportion of P53-positive cells was significantly higher in serous adenocarcinomas than in mucinous adenocarcinomas. P53 overexpression may therefore be closely related to the early events of carcinogenesis in serous tumors. Although mutation of the K-ras oncogene appears to be an important event in the early tumorigenesis of mucinous tumors, mutation of the K-ras oncogene in serous tumors may be dependent on morphology. Different complex pathways of oncogene and/or tumor suppressor gene abnormalities may be involved in the development of mucinous and serous adenocarcinomas.

Entities:  

Mesh:

Year:  2000        PMID: 10792785     DOI: 10.1046/j.1440-1827.2000.01028.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  3 in total

Review 1.  Oligonucleotide treatment of ras-induced tumors in nude mice.

Authors:  E Wickstrom
Journal:  Mol Biotechnol       Date:  2001-05       Impact factor: 2.695

2.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.

Authors:  Sandra Orsulic; Yi Li; Robert A Soslow; Lynn A Vitale-Cross; J Silvio Gutkind; Harold E Varmus
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

3.  Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.

Authors:  Anne L Estep; Chana Palmer; Frank McCormick; Katherine A Rauen
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.